Literature DB >> 9736697

Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases.

T K Sengupta1, E S Talbot, P A Scherle, L B Ivashkiv.   

Abstract

Gene activation and cellular differentiation induced by interleukin-6 (IL-6) and transcription factor Stat3 are suppressed by several factors, including ionomycin, granulocyte/macrophage-colony-stimulating factor, and phorbol 12-myristate 13-acetate (PMA), that block IL-6-induced Stat3 activation. These inhibitory agents activate mitogen activated protein kinases (MAPKs), and thus the role of MAPKs in the mechanism of inhibition of Stat3 activation was investigated. Inhibition of IL-6-induced Stat3 activation by PMA and ionomycin was rapid (within 5 min) and did not require new RNA or protein synthesis. Inhibition of Stat3 DNA-binding activity and tyrosine phosphorylation by PMA, ionomycin, and granulocyte/macrophage-colony-stimulating factor was reversed when activation of the extracellular signal-regulated kinase (ERK) group of MAPKs was blocked by using specific kinase inhibitors. Expression of constitutively active MEK1, the kinase that activates ERKs, or overexpression of ERK2, but not JNK1, inhibited Stat3 activation. Inhibition of Stat3 correlated with suppression of IL-6-induction of a signal transducer and activator of transcription (STAT)-dependent reporter gene. In contrast to IL-6, activation of Stat3 by interferon-alpha was not inhibited. MEKs and ERKs inhibited IL-6 activation of Stat3 harboring a mutation at serine-727, the major site for serine phosphorylation, similar to inhibition of wild-type Stat3, and inhibited Janus kinases Jak1 and Jak2 upstream of Stat3 in the Jak-STAT-signaling pathway. These results demonstrate an ERK-mediated mechanism for inhibiting IL-6-induced Jak-STAT signaling that is rapid and inducible, and thus differs from previously described mechanisms for downmodulation of the Jak-STAT pathway. This inhibitory pathway provides a molecular mechanism for the antagonism of Stat3-mediated IL-6 activity by factors that activate ERKs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736697      PMCID: PMC21603          DOI: 10.1073/pnas.95.19.11107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Structure and function of a new STAT-induced STAT inhibitor.

Authors:  T Naka; M Narazaki; M Hirata; T Matsumoto; S Minamoto; A Aono; N Nishimoto; T Kajita; T Taga; K Yoshizaki; S Akira; T Kishimoto
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

2.  A new protein containing an SH2 domain that inhibits JAK kinases.

Authors:  T A Endo; M Masuhara; M Yokouchi; R Suzuki; H Sakamoto; K Mitsui; A Matsumoto; S Tanimura; M Ohtsubo; H Misawa; T Miyazaki; N Leonor; T Taniguchi; T Fujita; Y Kanakura; S Komiya; A Yoshimura
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

3.  TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes.

Authors:  J J Bright; L D Kerr; S Sriram
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

5.  Functionally distinct isoforms of STAT5 are generated by protein processing.

Authors:  M Azam; C Lee; I Strehlow; C Schindler
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

6.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

7.  The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation.

Authors:  F Mainiero; C Murgia; K K Wary; A M Curatola; A Pepe; M Blumemberg; J K Westwick; C J Der; F G Giancotti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

8.  STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase.

Authors:  T G Boulton; Z Zhong; Z Wen; J E Darnell; N Stahl; G D Yancopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

9.  Requirement of serine phosphorylation for formation of STAT-promoter complexes.

Authors:  X Zhang; J Blenis; H C Li; C Schindler; S Chen-Kiang
Journal:  Science       Date:  1995-03-31       Impact factor: 47.728

10.  Regulation of interleukin-12 by complement receptor 3 signaling.

Authors:  T Marth; B L Kelsall
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

View more
  58 in total

1.  Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids.

Authors:  M Bianchi; C Meng; L B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

3.  Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway.

Authors:  Zhimei Du; Yuhong Shen; Wentian Yang; Ingrid Mecklenbrauker; Benjamin G Neel; Lionel B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-06       Impact factor: 11.205

Review 4.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

5.  Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons.

Authors:  D I Orellana; R A Quintanilla; C Gonzalez-Billault; R B Maccioni
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

6.  SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts.

Authors:  Lerin R Luckett-Chastain; Michael A Ihnat; Bethany M Mickle-Kawar; Randle Michael Gallucci
Journal:  J Interferon Cytokine Res       Date:  2012-02-07       Impact factor: 2.607

7.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

8.  Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Tatiana M Fontelonga; Brennan Jordan; Andreia M Nunes; Pamela Barraza-Flores; Nicholas Bolden; Ryan D Wuebbles; Lesley Mathews Griner; Xin Hu; Marc Ferrer; Juan Marugan; Noel Southall; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

9.  Zinc ameliorates intestinal barrier dysfunctions in shigellosis by reinstating claudin-2 and -4 on the membranes.

Authors:  Paramita Sarkar; Tultul Saha; Irshad Ali Sheikh; Subhra Chakraborty; Joydeep Aoun; Manoj Kumar Chakrabarti; Vazhaikkurichi M Rajendran; Nadia A Ameen; Shanta Dutta; Kazi Mirajul Hoque
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-08       Impact factor: 4.052

10.  Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway.

Authors:  Dairmuid M Moran; M Adrian Mattocks; Paul A Cahill; Leonidas G Koniaris; Iain H McKillop
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.